Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Voyager Therapeutics, Inc. (Nasdaq: VYGR) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures, including current reports on Form 8-K that furnish financial results, corporate updates, and investor presentations. As a Delaware-incorporated public company with common stock listed on the Nasdaq Global Select Market, Voyager files with the U.S. Securities and Exchange Commission to report material information related to its biotechnology business focused on neurological diseases.
Through these filings, readers can access details on Voyager’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities. The company’s 8-K filings often attach press releases that describe quarterly financial and operating results, cash runway expectations, and progress across its pipeline, including Alzheimer’s disease programs such as the anti-tau antibody VY7523 and tau silencing gene therapy VY1706, as well as partnered gene therapy programs with Neurocrine Biosciences and collaborations with Novartis and other partners.
Voyager’s filings also reference its TRACER™ AAV capsid discovery platform, next-generation capsids designed for blood-brain barrier penetration, and collaborations such as the small molecule discovery and license option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia. Forward-looking statements and risk disclosures in these documents outline uncertainties related to regulatory decisions, clinical development, collaboration milestones, intellectual property, and the company’s ability to fund operations.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major financial metrics, pipeline updates, and collaboration terms. Users can follow new 8-Ks and other SEC reports in real time, review historical filings for context on Voyager’s evolution, and connect these disclosures to the company’s news flow and stock performance.
Voyager Therapeutics, Inc. officer Gregory L. Shiferman filed an initial ownership report on Form 3 stating that, as of 01/06/2026, he beneficially owns no securities of the company. He is identified as Senior Vice President and General Counsel, and the filing is made by a single reporting person.
Voyager Therapeutics, Inc. filed a Form 8-K to inform investors that it has posted an updated corporate investor presentation on the Investors section of its website and will distribute a letter summarizing key points from that presentation to certain stockholders. These materials are included as Exhibits 99.1 and 99.2 and are furnished, rather than filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced. The materials and related forward-looking statements discuss Voyager’s preclinical and clinical development plans, potential expansion into additional neurogenetic medicine modalities, collaboration and licensing arrangements, and the expected sufficiency of its cash resources, all subject to significant scientific, regulatory, collaboration, and funding risks outlined in the company’s risk disclosures.
Voyager Therapeutics, Inc. filed a mixed shelf registration to offer up to $400,000,000 of securities, including common and preferred stock, debt, depositary shares, subscription rights, warrants, purchase contracts, and units, in one or more offerings after this registration statement becomes effective.
The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock with TD Securities (USA) LLC (TD Cowen), which is part of the $400,000,000 shelf. Proceeds, if and when raised, may be used for general corporate purposes such as R&D, advancing programs into clinical development, regulatory activities, working capital, and potential in-licenses or acquisitions. Voyager’s common stock trades on Nasdaq as VYGR. Shares outstanding were 55,600,084 as of November 3, 2025.
Voyager Therapeutics, Inc. filed a mixed shelf registration to offer up to $400,000,000 of securities, including common and preferred stock, debt, depositary shares, subscription rights, warrants, purchase contracts, and units, in one or more offerings after this registration statement becomes effective.
The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock with TD Securities (USA) LLC (TD Cowen), which is part of the $400,000,000 shelf. Proceeds, if and when raised, may be used for general corporate purposes such as R&D, advancing programs into clinical development, regulatory activities, working capital, and potential in-licenses or acquisitions. Voyager’s common stock trades on Nasdaq as VYGR. Shares outstanding were 55,600,084 as of November 3, 2025.
Voyager Therapeutics reported Q3 2025 results showing lower collaboration revenue and a wider loss as it advances its neurology pipeline. Collaboration revenue was $13.4 million versus $24.6 million a year ago, while operating expenses rose to $44.0 million from $38.4 million, driving a net loss of $27.9 million compared with $9.0 million in Q3 2024. For the first nine months, collaboration revenue was $25.0 million versus $73.7 million a year earlier, with a net loss of $92.3 million.
Cash, cash equivalents, and marketable securities totaled $229.0 million as of September 30, 2025, and management expects this to fund operations for at least 12 months. The company continues to invest in Alzheimer’s programs VY7523 (anti‑tau antibody, Phase 1 MAD started in early AD) and VY1706 (tau‑silencing gene therapy, IND planned in 2026). A subsequent event notes Novartis’ partial termination of a 2022 option and license agreement for two programs effective February 1, 2026; one Novartis program remains under that agreement.
Voyager Therapeutics reported Q3 2025 results showing lower collaboration revenue and a wider loss as it advances its neurology pipeline. Collaboration revenue was $13.4 million versus $24.6 million a year ago, while operating expenses rose to $44.0 million from $38.4 million, driving a net loss of $27.9 million compared with $9.0 million in Q3 2024. For the first nine months, collaboration revenue was $25.0 million versus $73.7 million a year earlier, with a net loss of $92.3 million.
Cash, cash equivalents, and marketable securities totaled $229.0 million as of September 30, 2025, and management expects this to fund operations for at least 12 months. The company continues to invest in Alzheimer’s programs VY7523 (anti‑tau antibody, Phase 1 MAD started in early AD) and VY1706 (tau‑silencing gene therapy, IND planned in 2026). A subsequent event notes Novartis’ partial termination of a 2022 option and license agreement for two programs effective February 1, 2026; one Novartis program remains under that agreement.
Voyager Therapeutics, Inc. filed a Form 8-K to report that it announced its third quarter 2025 financial results and corporate updates. The company did this by issuing a press release dated November 10, 2025, which is included with the filing as Exhibit 99.1 under Item 2.02.
The press release is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced. The filing also identifies Voyager’s common stock, traded on the Nasdaq Global Select Market under the symbol VYGR, and is signed by Alfred Sandrock, M.D., Ph.D., the company’s Chief Executive Officer, President, and Director.
Voyager Therapeutics, Inc. filed a Form 8-K to report that it announced its third quarter 2025 financial results and corporate updates. The company did this by issuing a press release dated November 10, 2025, which is included with the filing as Exhibit 99.1 under Item 2.02.
The press release is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced. The filing also identifies Voyager’s common stock, traded on the Nasdaq Global Select Market under the symbol VYGR, and is signed by Alfred Sandrock, M.D., Ph.D., the company’s Chief Executive Officer, President, and Director.
Voyager Therapeutics, Inc. (VYGR) Chief Financial Officer Nathan D. Jorgensen reported the sale of 7,666 shares of common stock on 10/03/2025. The sales were executed under a pre-existing durable automatic sales instruction (a sell-to-cover election) tied to the vesting of restricted stock units, to satisfy tax withholding. The weighted-average price reported for the shares sold was $4.78, with individual trade prices ranging from $4.74 to $4.85. After the reported transaction, the reporting person beneficially owned 123,834 shares of common stock.
Voyager Therapeutics (VYGR) filed a Form 144 notice for a proposed sale of 5,843 common shares. The shares carry an aggregate market value of $27,936.55 and are slated for sale through Fidelity Brokerage Services LLC on or about 10/03/2025 on the NASDAQ.
The securities were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. This is a routine compliance notice that permits the holder to sell these shares under Rule 144, subject to applicable volume and manner-of-sale conditions.
VYGR: A holder filed a Form 144 notice to sell 7,666 shares of common stock. The filing lists an aggregate market value of $36,633.51 and an approximate sale date of 10/03/2025, with sales through Fidelity Brokerage Services LLC on NASDAQ.
The shares were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 55,468,806; this is a baseline figure, not the amount being sold.
Voyager Therapeutics, Inc. furnished an investor presentation in connection with its appearance at Citi’s 2025 Biopharma Back to School Conference. The company plans to present the materials in Exhibit 99.1 on September 2, 2025 at 4:00 p.m. ET.
The presentation is being provided under Regulation FD and, along with Item 7.01, is treated as “furnished” rather than “filed,” which limits certain securities law liabilities and incorporation by reference. Voyager states it is not admitting the materiality of the information and notes that these materials should be read together with its other SEC filings and public disclosures, and it does not undertake an obligation to update them.
Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported the sale of 19,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $3.73 per share. After the reported sale, Mr. Ferguson beneficially owned 138,914 shares, held directly. The filing discloses that the $3.73 figure is a weighted average for multiple transactions executed at prices ranging from $3.69 to $3.79 and states the reporting person will provide a detailed breakdown of shares sold at each price on request. The Form 4 was signed by an attorney-in-fact on 08/20/2025.